These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 16260168)

  • 1. Coccidioidal pericarditis.
    Arsura EL; Bobba RK; Reddy CM
    Int J Infect Dis; 2006 Jan; 10(1):86-7. PubMed ID: 16260168
    [No Abstract]   [Full Text] [Related]  

  • 2. ABLE: a new and improved amphotericin B for visceral leishmaniasis?
    Berman J
    Am J Trop Med Hyg; 2009 May; 80(5):689-90. PubMed ID: 19407106
    [No Abstract]   [Full Text] [Related]  

  • 3. Successful treatment of visceral leishmaniasis with liposomal amphotericin B.
    Lagler H; Matt U; Sillaber C; Winkler S; Graninger W
    Acta Biomed; 2006; 77 Suppl 2():22-5. PubMed ID: 16918063
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Coccidioidal pericarditis: a case presentation and review of the literature.
    Arsura EL; Bobba RK; Reddy CM
    Int J Infect Dis; 2005 Mar; 9(2):104-9. PubMed ID: 15708326
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Diffuse cutaneous dissemination of visceral leishmaniasis during human immunodeficiency virus (HIV) infection, despite negligible immunodeficiency: repeated failure of liposomal amphotericin B administration, followed by successful long-term pentamidine and paromomycin administration.
    Manfredi R; Marinacci G; Calza L; Passarini B
    Int J Antimicrob Agents; 2008 Jun; 31(6):590-2. PubMed ID: 18456464
    [No Abstract]   [Full Text] [Related]  

  • 6. Liposomal amphotericin B for the treatment of visceral leishmaniasis.
    Bern C; Adler-Moore J; Berenguer J; Boelaert M; den Boer M; Davidson RN; Figueras C; Gradoni L; Kafetzis DA; Ritmeijer K; Rosenthal E; Royce C; Russo R; Sundar S; Alvar J
    Clin Infect Dis; 2006 Oct; 43(7):917-24. PubMed ID: 16941377
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Amphotericin B colloidal dispersion for the treatment of Indian visceral leishmaniasis.
    Sundar S; Mehta H; Chhabra A; Singh V; Chauhan V; Desjeux P; Rai M
    Clin Infect Dis; 2006 Mar; 42(5):608-13. PubMed ID: 16447104
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Studies on the mode of action of quinolone and pyridone coccidiostats.
    Ryley JF
    J Parasitol; 1967 Dec; 53(6):1151-60. PubMed ID: 6078603
    [No Abstract]   [Full Text] [Related]  

  • 9. Highly effective oral amphotericin B formulation against murine visceral leishmaniasis.
    Wasan KM; Wasan EK; Gershkovich P; Zhu X; Tidwell RR; Werbovetz KA; Clement JG; Thornton SJ
    J Infect Dis; 2009 Aug; 200(3):357-60. PubMed ID: 19545212
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antileishmanial activity of nano-amphotericin B deoxycholate.
    Manandhar KD; Yadav TP; Prajapati VK; Kumar S; Rai M; Dube A; Srivastava ON; Sundar S
    J Antimicrob Chemother; 2008 Aug; 62(2):376-80. PubMed ID: 18453526
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Naegleria meningitis.
    Singh SN; Patwari AK; Dutta R; Taneja N; Anand VK
    Indian Pediatr; 1998 Oct; 35(10):1012-5. PubMed ID: 10216726
    [No Abstract]   [Full Text] [Related]  

  • 12. [A case of antimony resistant kala-azar cured with amphotericin B].
    Chen SB; Yang CM; Zhang CJ
    Zhongguo Ji Sheng Chong Xue Yu Ji Sheng Chong Bing Za Zhi; 2007 Jun; 25(3):inside front page. PubMed ID: 18038767
    [No Abstract]   [Full Text] [Related]  

  • 13. EXTENSION OF THE KNOWN HOST RANGE OF INTRANUCLEAR COCCIDIOSIS: INFECTION IN THREE CAPTIVE RED-FOOTED TORTOISES ( CHELONOIDIS CARBONARIA).
    Stilwell JM; Stilwell NK; Stacy NI; Wellehan JFX; Farina LL
    J Zoo Wildl Med; 2017 Dec; 48(4):1165-1171. PubMed ID: 29297806
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Leishmaniasis due to L. infantum presenting as macrocheilitis and responding to liposomal amphotericin B.
    Rongioletti F; Cannata GE; Parodi A
    Eur J Dermatol; 2009; 19(3):281-2. PubMed ID: 19286487
    [No Abstract]   [Full Text] [Related]  

  • 15. Treatment of mucosal leishmaniasis with a lipid formulation of amphotericin B.
    Amato VS; Tuon FF; Campos A; Bacha HA; Nicodemo AC; Amato Neto V; Shikanai-Yasuda MA
    Clin Infect Dis; 2007 Jan; 44(2):311-2. PubMed ID: 17173238
    [No Abstract]   [Full Text] [Related]  

  • 16. [Leishmania braziliensis: report of a pediatric imported case with response to liposomal amphotericin B].
    Campos-Muñoz L; Quesada-Cortés A; Martín-Díaz MA; Rubio-Flores C; de Lucas-Laguna R
    Actas Dermosifiliogr; 2007; 98(1):42-4. PubMed ID: 17374332
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Cryptosporidiosis in man].
    Henkel G
    MMW Munch Med Wochenschr; 1983 Nov; 125(47):1099-102. PubMed ID: 6419066
    [No Abstract]   [Full Text] [Related]  

  • 18. Anthropometrically derived dosing and drug costing calculations for treating visceral leishmaniasis in Bihar, India.
    Olliaro P; Sundar S
    Trop Med Int Health; 2009 Jan; 14(1):88-92. PubMed ID: 19121150
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comment on: Unresponsiveness to AmBisome in some Sudanese patients with kala-azar.
    de Górgolas M
    Trans R Soc Trop Med Hyg; 2007 Oct; 101(10):1054; author reply 1054-5. PubMed ID: 17651771
    [No Abstract]   [Full Text] [Related]  

  • 20. A cautionary tale.
    Elgouhari HM; Kellie SM
    Am J Med; 2007 Mar; 120(3):225-8. PubMed ID: 17349441
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.